The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 11 - 20 of 76
HIV Prevention Research and Development Database
The HIV Prevention Research & Development Database is a comprehensive source of information on biomedical HIV prevention clinical trials that are planned, ongoing or completed. The database allows users to view clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
AVAC’s Plan for Accelerating Access and Introduction of Injectable Cabotegravir (CAB) for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years…
AIDSVu is an interactive online mapping tool that visualizes the impact of the HIV epidemic on communities across the United States to increase disease awareness and promote data-driven public health decision-making. This includes information on PrEP use and need from national to city level.
Monitoring & Evaluation
Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women
This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.
AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long- acting injectable cabotegravir for HIV prevention
AVAC press release announcing a new collaboration focused on pricing, innovative funding mechanisms, tracking regulatory approvals, and ensuring the inclusion of civil society in key planning and decision making to speed access to injectable cabotegravir (CAB) for PrEP. Launched at the 24th International AIDS Conference, this collaboration includes AVAC, the Bill and Melinda Gates Foundation,…
ViiV and Medicines Patent Pool Sign Voluntary Licensing Agreement for Cabotegravir for PrEP
ViiV Healthcare and the Medicines Patent Pool (MPP) announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir for PrEP to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries.
Service Delivery, Supply Chain Management
The Brazilian government offers this monitoring panel which tracks national data on PrEP delivery.
Zambia Adolescent HIV Care and Treatment Training Curriculum
This standardized curriculum empowers multidisciplinary health workers to have the confidence and skills to provide comprehensive, youth-friendly HIV services that support adolescents’ health development, psychosocial well-being, retention, adherence, sexual reproductive health, and eventual transition to adult HIVservices. The training curriculum includes a 15-module Trainer Manual, a Participant Manual, and accompanying PowerPoint slides.
Eswatini National AIDS Program Monitoring & Evaluation
Eswatini's National AIDS Program (ENAP), formerly known as Swaziland National AIDS Program (SNAP), is the coordinating body responsible for tracking and responding to the HIV/AIDS epidemic in the country. The Monitoring and Evaluation Unit works directly with ENAP to track social intervetions within country.
Appropriate medicines: options for pre-exposure prophylaxis (WHO, 2018)
In March 2016, WHO and UNAIDS jointly convened a technical group of experts in antiretroviral (ARV) pharmacology and HIV pre-exposure prophylaxis (PrEP) clinical research to provide clarifications related to three specific implementation concerns for countries regarding the appropriate use of PrEP drug regimens: possible use of lamivudine (3TC) as an alternative to emtricitabine (FTC) for…